218. Alport syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 30 / Drugs : 36 - (DrugBank : 15) / Drug target genes : 8 - Drug target pathways : 46
Alport syndrome and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
| ID | Diseases (Sorted by drug repositionability) |
|---|---|
| 218 | Alport syndrome |
| 66 | IgA nephropathy |
| 222 | Primary nephrotic syndrome |
| 86 | Pulmonary arterial hypertension |
| 67 | Polycystic kidney disease |
| 58 | Hypertrophic cardiomyopathy |
| 113 | Muscular dystrophy |
| 97 | Ulcerative colitis |
| 96 | Crohn disease |
| 46 | Malignant rheumatoid arthritis |
| 6 | Parkinson disease |
| 210 | Single Ventricle |
| 271 | Ankylosing spondylitis |
| 17 | Multiple system atrophy |
| 75 | Cushing disease |
| 19 | Lysosomal storage disease |
| 84 | Sarcoidosis |
| 299 | Cystic fibrosis |
| 85 | Idiopathic interstitial pneumonia |
| 51 | Scleroderma |
| 49 | Systemic lupus erythematosus |
| 13 | Multiple sclerosis/Neuromyelitis optica |